Full-Time

Field Sales Consultant

Medical, Miami/Fort Lauderdale

Henry Schein

Henry Schein

10,001+ employees

Global healthcare product distributor and services

No salary listed

Florida, USA

Remote

Category
Sales & Account Management (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • High School diploma
  • A valid US Driver's License (Motor Vehicle Check Required)
  • Ability to travel extensively within a specific geographic territory
  • Not afraid of cold calling and are delighted to drive meaningful conversations with prospective customers and build relationships
  • Excellent communication skills with prior sales experience, customer service, presentation, and negotiation skills
  • PC proficiency, including MS Word and Excel
Responsibilities
  • Plan, organize and implement effective strategies using company resources and other initiatives to increase market share within a specific territory by coordinating all team selling assets including, Telesales, Business Development Executives, Strategic Accounts Team, Lab and Diagnostics / Equipment Team, Surgical Solutions Team and others
  • Conduct face-to-face contact with every account assigned and captured on a timely and periodic basis
  • Passionately respond to customers’ concerns and resolve inquiries promptly to ensure customer satisfaction
  • Attend medical conventions/seminars and participate in all training programs to enhance sales and business acumen and subsequent sales performance
Desired Qualifications
  • Bachelor’s degree highly preferred
  • Prior sales experience helpful but not required

Henry Schein is a global supplier of healthcare products and services. It operates in two segments: healthcare distribution, which provides dental and medical consumables, equipment, and laboratory products to dentists, physicians, and veterinarians; and technology and value-added services, which offers practice management software, e-commerce solutions, and financial services. The company works by supplying healthcare professionals with a broad range of products and by offering software, online tools, and financing options to run their practices more efficiently. Compared with competitors, Henry Schein combines a wide product catalog with software and financial services, creating a one-stop platform for practice needs across more than 30 countries, with a strong focus on North America. Its goal is to be a trusted partner for healthcare professionals by supporting their day-to-day operations and growth through integrated distribution, technology, and financing solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Huntington, New York

Founded

1932

Your Connections

People at Henry Schein who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Management targets over $200 million in operating profit improvements.
  • The August 2026 e-commerce rollout should deepen digital ordering and retention.
  • High-growth businesses represented nearly half of operating income in Q1 2026.

What critics are saying

  • Benco Dental and Patterson are pressuring U.S. dental margins.
  • Large DSOs centralize procurement, reducing Henry Schein's pricing power.
  • Mild flu seasons weaken medical diagnostics demand and distort quarterly results.

What makes Henry Schein unique

  • Henry Schein combines global healthcare distribution with practice-management software.
  • It serves dentists, physicians, and veterinarians across more than 30 countries.
  • Its one-stop model pairs consumables, equipment, financing, and e-commerce.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Parental Leave

Short Term Disability

Health Savings Account/Flexible Spending Account

Education Benefits

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Apr 9th, 2026
Henry Schein board to shrink from 15 to 10 members as Stanley Bergman retires after 44 years

Henry Schein has announced its board will shrink from 15 to 10 members following its 2026 annual meeting, with longtime director and former chairman Stanley Bergman retiring after 44 years alongside four other directors not standing for re-election. The board reshaping coincides with Frederick Lowery's appointment as chief executive, effective March 2026, framing the changes as part of a broader leadership transition. This governance shift adds uncertainty to Henry Schein's ongoing transformation, which includes a push towards higher-margin software and specialty products alongside cost-saving initiatives driven by KKR. Analysts project $14.8 billion revenue and $595.4 million earnings by 2029. The company's narrative suggests continued focus on digital offerings, specialty products and international expansion under new leadership.

Fortune
Mar 27th, 2026
South African expat built $13B Fortune 500 firm fleeing apartheid at 26

Stanley Bergman, who fled apartheid South Africa at 26, stepped down this month as CEO of Henry Schein after 36 years leading the company. He transformed the regional dental supplier from $225 million in revenue to a $13.2 billion Fortune 500 medical and dental distributor. Bergman joined as CFO in 1980, attracted by the founders' commitment to aligning business with social values. Under his leadership, Henry Schein appeared on Fortune's World's Most Admired Companies list for 21 consecutive years. His leadership philosophy emphasised hiring for character over credentials, diversifying perspectives, expanding through joint ventures, and serving society alongside stakeholders. The company's "Give Kids a Smile" initiative provides free dental screenings to over 300,000 children annually. Fred Lowery succeeded Bergman as CEO on 2 March, with Bergman remaining chairman.

Yahoo Finance
Mar 6th, 2026
$13.2B healthcare supplier Henry Schein opens training centre and showroom in Southlake

Henry Schein, a $9 billion global healthcare supplier, has opened its first integrated training facility in Southlake, Texas. The Dallas Discovery Center spans 8,300 square feet at 1080 S. Kimball Ave., featuring eight experience labs, two training rooms, a boardroom and an attached warehouse. The facility serves as both a training centre for sales associates and a showroom for potential clients. It includes fully equipped dental labs, an ambulatory surgery room, 3D printing stations, sterilisation equipment and a functioning laboratory with blood-drawing and diagnostic tools. Henry Schein, headquartered in Melville, New York, recorded $13.2 billion in sales across 34 countries in 2025. The company previously opened an 811,000-square-foot distribution centre in Alliance in 2024. New CEO Frederick Lowery attended the facility's opening on 2nd March.

Business Wire
Mar 3rd, 2026
Henry Schein to present at Leerink and Barclays healthcare conferences in March

Henry Schein, the world's largest provider of healthcare solutions to office-based dental and medical practitioners, will present at two investor conferences in March. The company will appear at Leerink's Global Healthcare Conference in Miami on 9 March at 10:00 EST and Barclays 28th Annual Global Healthcare Conference on 10 March at 10:30 EST. Both presentations will be available via live webcast on the company's website, with replays accessible afterwards. Henry Schein, a FORTUNE 500 company headquartered in Melville, New York, operates in 34 countries and serves over one million customers globally. The company reported sales of $13.2 billion in 2025.

Yahoo Finance
Feb 26th, 2026
Henry Schein price targets lifted to $87–$104 as dental demand shows rebound

Henry Schein's assessed fair value has risen to $83.21 from $78.14, aligning with multiple analyst upgrades that lifted price targets to the $87–$100 range. Several firms, including Baird, Evercore ISI and JPMorgan, raised targets following improved dental demand indicators and Q4 results. Baird cited three consecutive months of modest patient demand rebound and forecast double-digit earnings growth starting in 2027, lifting its target to $104. However, UBS, Mizuho and Leerink maintained cautious neutral ratings despite modest target increases to $87–$88. The company appointed Frederick Lowery as CEO effective 2 March 2026, whilst Stanley Bergman transitions to Chairman after 35 years. Henry Schein guided 2026 sales growth of 3–5% and repurchased 2.8 million shares for $200 million.